Angiotensin-Converting Enzyme 2 as a Therapeutic Target for Heart Failure

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

1. 1.
   Wang W, Bodiga S, Das SK, Lo J, Patel V, Oudit GY. Role of ACE2 in diastolic and systolic heart failure. Heart Fail Rev. 2012;17(4–5):683–91.PubMedCrossRefGoogle Scholar
2. 2.
   • Oudit GY, Crackower MA, Backx PH, Penninger JM. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med. 2003;13(3):93–101. Comprehensive review on the current physiologic understanding of ACE2 in cardiovascular diseases.PubMedCrossRefGoogle Scholar
3. 3.
   Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275(43):33238–43.PubMedCrossRefGoogle Scholar
4. 4.
   Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res. 2000;87(5):E1–9.PubMedCrossRefGoogle Scholar
5. 5.
   Burrell LM, Harrap SB, Velkoska E, Patel SK. The ACE2 gene: its potential as a functional candidate for cardiovascular disease. Clin Sci (Lond). 2013;124(2):65–76.CrossRefGoogle Scholar
6. 6.
   Iwata M, Cowling RT, Yeo SJ, Greenberg B. Targeting the ACE2-Ang-(1–7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure. J Mol Cell Cardiol. 2011;51(4):542–7.PubMedCentralPubMedCrossRefGoogle Scholar
7. 7.
   •• Oudit GY, Penninger JM. Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy. Curr Heart Fail Rep. 2011;8(3):176–83. First demonstration of the feasibility and beneficial effects of recumbinant human ACE2 as potential therapy.PubMedCrossRefGoogle Scholar
8. 8.
   Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277(17):14838–43.PubMedCrossRefGoogle Scholar
9. 9.
   Fraga-Silva RA, Costa-Fraga FP, Murca TM, et al. Angiotensin-converting enzyme 2 activation improves endothelial function. Hypertension. 2013;61(6):1233–8.PubMedCrossRefGoogle Scholar
10. 10.
    Keidar S, Gamliel-Lazarovich A, Kaplan M, et al. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res. 2005;97(9):946–53.PubMedCrossRefGoogle Scholar
11. 11.
    Silva AC S e, Silveira KD, Ferreira AJ, Teixeira MM. ACE2, angiotensin-(1–7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol. 2013;169(3):477–92.CrossRefGoogle Scholar
12. 12.
    Zhong JC, Ye JY, Jin HY, et al. Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regul Pept. 2011;166(1–3):90–7.PubMedCrossRefGoogle Scholar
13. 13.
    Clarke NE, Fisher MJ, Porter KE, Lambert DW, Turner AJ. Angiotensin converting enzyme (ACE) and ACE2 bind integrins and ACE2 regulates integrin signalling. PLoS One. 2012;7(4):e34747.PubMedCentralPubMedCrossRefGoogle Scholar
14. 14.
    Lin Q, Keller RS, Weaver B, Zisman LS. Interaction of ACE2 and integrin beta1 in failing human heart. Biochim Biophys Acta. 2004;1689(3):175–8.PubMedCrossRefGoogle Scholar
15. 15.
    Sato T, Suzuki T, Watanabe H, et al. Apelin is a positive regulator of ACE2 in failing hearts. J Clin Invest 2013.Google Scholar
16. 16.
    Zhong J, Basu R, Guo D, et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation. 2010;122(7):717–28. 718 p following 728.PubMedCrossRefGoogle Scholar
17. 17.
    • Kassiri Z, Zhong J, Guo D, et al. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail. 2009;2(5):446–55. Important demonstration of the cardioprotective role of ACE2.PubMedCrossRefGoogle Scholar
18. 18.
    Tikellis C, Bernardi S, Burns WC. Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens. 2011;20(1):62–8.PubMedCrossRefGoogle Scholar
19. 19.
    Oudit GY, Kassiri Z, Patel MP, et al. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res. 2007;75(1):29–39.PubMedCrossRefGoogle Scholar
20. 20.
    Bodiga S, Zhong JC, Wang W, et al. Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47(phox) NADPH oxidase subunit. Cardiovasc Res. 2011;91(1):151–61.PubMedCrossRefGoogle Scholar
21. 21.
    Huentelman MJ, Grobe JL, Vazquez J, et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol. 2005;90(5):783–90.PubMedCrossRefGoogle Scholar
22. 22.
    Yamamoto K, Ohishi M, Katsuya T, et al. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension. 2006;47(4):718–26.PubMedCrossRefGoogle Scholar
23. 23.
    Santos RA, Ferreira AJ, ESAC Simoes. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1–7)-Mas axis. Exp Physiol. 2008;93(5):519–27.PubMedCrossRefGoogle Scholar
24. 24.
    Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 Of the heart: from angiotensin I to angiotensin (1–7). Cardiovasc Res. 2007;73(3):463–9.PubMedCrossRefGoogle Scholar
25. 25.
    Grobe JL, Der Sarkissian S, Stewart JM, Meszaros JG, Raizada MK, Katovich MJ. ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts. Clin Sci (Lond). 2007;113(8):357–64.CrossRefGoogle Scholar
26. 26.
    Zhao YX, Yin HQ, Yu QT, et al. ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction. Hum Gene Ther. 2010;21(11):1545–54.PubMedCrossRefGoogle Scholar
27. 27.
    Lazartigues E, Feng Y, Lavoie JL. The two fACEs of the tissue renin-angiotensin systems: implication in cardiovascular diseases. Curr Pharm Des. 2007;13(12):1231–45.PubMedCrossRefGoogle Scholar
28. 28.
    Imai Y, Kuba K, Ohto-Nakanishi T, Penninger JM. Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ J. 2010;74(3):405–10.PubMedCrossRefGoogle Scholar
29. 29.
    Zisman LS, Keller RS, Weaver B, et al. Increased angiotensin-(1–7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation. 2003;108(14):1707–12.PubMedCrossRefGoogle Scholar
30. 30.
    Goulter AB, Goddard MJ, Allen JC, Clark KL. ACE2 gene expression is up-regulated in the human failing heart. BMC Med. 2004;2:19.PubMedCentralPubMedCrossRefGoogle Scholar
31. 31.
    Ohtsuki M, Morimoto S, Izawa H, et al. Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure. Int J Cardiol. 2010;145(2):333–4.PubMedCrossRefGoogle Scholar
32. 32.
    • Epelman S, Tang WH, Chen SY, Van Lente F, Francis GS, Sen S. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol. 2008;52(9):750–4. Demonstration of the clinical relevance of ACE2 in humans by detecting circulating ACE2 activity and its associations with disease severity.PubMedCentralPubMedCrossRefGoogle Scholar
33. 33.
    Epelman S, Shrestha K, Troughton RW, et al. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail. 2009;15(7):565–71.PubMedCentralPubMedCrossRefGoogle Scholar
34. 34.
    Wang Y, Moreira Mda C, Heringer-Walther S, et al. Plasma ACE2 activity is an independent prognostic marker in Chagas' disease and equally potent as BNP. J Card Fail. 2010;16(2):157–63.PubMedCrossRefGoogle Scholar
35. 35.
    Shao Z, Shrestha K, Borowski AG, et al. Increasing serum soluble angiotensin-converting enzyme 2 activity after intensive medical therapy is associated with better prognosis in acute decompensated heart failure. J Card Fail. 2013;19(9):605–10.PubMedCrossRefGoogle Scholar
36. 36.
    Wysocki J, Ye M, Rodriguez E, et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension. 2010;55(1):90–8.PubMedCentralPubMedCrossRefGoogle Scholar
37. 37.
    Gallagher PE, Ferrario CM, Tallant EA. Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol. 2008;295(6):H2373–9.PubMedCrossRefGoogle Scholar
38. 38.
    Lu N, Yang Y, Wang Y, et al. ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects. Mol Biol Rep. 2012;39(6):6581–9.PubMedCrossRefGoogle Scholar
39. 39.
    Vangjeli C, Dicker P, Tregouet DA, Shields DC, Evans A, Stanton AV. A polymorphism in ACE2 is associated with a lower risk for fatal cardiovascular events in females: the MORGAM project. J Renin Angiotensin Aldosterone Syst. 2011;12(4):504–9.PubMedCrossRefGoogle Scholar
40. 40.
    Zhou JB, Yang JK. Meta-analysis of association of ACE2 G8790A polymorphism with Chinese Han essential hypertension. J Renin Angiotensin Aldosterone Syst. 2009;10(1):31–4.PubMedCrossRefGoogle Scholar
41. 41.
    Der Sarkissian S, Huentelman MJ, Stewart J, Katovich MJ, Raizada MK. ACE2: A novel therapeutic target for cardiovascular diseases. Prog Biophys Mol Biol. 2006;91(1–2):163–98.CrossRefGoogle Scholar
42. 42.
    • Hernandez Prada JA, Ferreira AJ, Katovich MJ, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008;51(5):1312–7. Promising work on identifying ACE2 activators as therapeutic agents.PubMedCrossRefGoogle Scholar
43. 43.
    Ferreira AJ, Jacoby BA, Araujo CA, et al. The nonpeptide angiotensin-(1–7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am J Physiol Heart Circ Physiol. 2007;292(2):H1113–9.PubMedCrossRefGoogle Scholar
44. 44.
    Patel VB, Bodiga S, Fan D, et al. Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1–7 in experimental heart failure in angiotensin-converting enzyme 2-null mice. Hypertension. 2012;59(6):1195–203.PubMedCrossRefGoogle Scholar
45. 45.
    Masson R, Nicklin SA, Craig MA, et al: Onset of experimental severe cardiacfibrosis is mediated by overexpression of Angiotensin-converting enzyme 2.Hypertension 2009, 53(4):694-700.Google Scholar
46. 46.
    Takahashi Y, Haga S, Ishizaka Y, Mimori A. Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases. Arthritis Res Ther. 2010;12(3):R85.PubMedCentralPubMedCrossRefGoogle Scholar